· Venture Capital · 1 source · Verified
David Protein Valuation: Medici Brands Raises $250M at $2.25B
Medici Brands, the parent company behind David, raised $250 million in a Series B at a reported $2.25 billion valuation. The valuation applies to the parent, not David as a separately priced company.
Editorial team
TL;DR: Medici Brands, the parent company behind David, raised a $250 million Series B in September 2026. CEO Peter Rahal said the parent was valued at $2.25 billion. That is the clean valuation figure; it should not be presented as if David itself completed a separate priced financing.
Deal details & investors
Funding event
David (Medici Brands)
Led by Greenoaks , Valor Equity Partners
Reported valuation $2.25B
Canonical profile: David / Medici Brands.
The financing
The Series B was co-led by Greenoaks and Valor Equity Partners, with participation from ICONIQ and Imaginary Ventures.
| Item | Figure |
|---|---|
| Series B | $250M |
| Parent-company valuation | $2.25B |
| Company | Medici Brands |
| Consumer brand | David |
Is David Protein worth $2.25 billion?
The careful answer is: Medici Brands was reported at a $2.25 billion valuation.
David is a brand operated by Medici Brands. Unless a financing separately prices the David legal entity, assigning the parent's entire valuation to the brand would overstate what the financing evidence actually shows.
Why the distinction matters
Private-company databases often collapse brand, operating company and holding company into one name. That makes search convenient but can distort the actual transaction.
VCT keeps the relationship explicit:
- David is the consumer-facing brand.
- Medici Brands is the parent company associated with the financing.
- $250M is the Series B amount.
- $2.25B is the reported parent-company valuation.
What to watch next
The durable questions are likely to be valuation, revenue, ownership, investors and whether the company eventually creates additional brands under the same parent. Future financings should be attached to the parent unless disclosures clearly establish a different borrower or issuer.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
